Form 8-K - Current report:
SEC Accession No. 0001193125-25-154062
Filing Date
2025-07-01
Accepted
2025-07-01 16:44:06
Documents
17
Period of Report
2025-06-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d943939d8k.htm   iXBRL 8-K 30572
2 EX-1.1 d943939dex11.htm EX-1.1 229636
3 EX-5.1 d943939dex51.htm EX-5.1 8065
4 EX-99.1 d943939dex991.htm EX-99.1 10144
8 GRAPHIC g943939g0701114015461.jpg GRAPHIC 2755
9 GRAPHIC g943939g0701114120212.jpg GRAPHIC 2038
  Complete submission text file 0001193125-25-154062.txt   468005

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA nktr-20250630.xsd EX-101.SCH 2835
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE nktr-20250630_lab.xml EX-101.LAB 17235
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nktr-20250630_pre.xml EX-101.PRE 10802
20 EXTRACTED XBRL INSTANCE DOCUMENT d943939d8k_htm.xml XML 3539
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 251097033
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)